| Literature DB >> 30105627 |
S Valade1,2, L Biard3,4, V Lemiale5,3, L Argaud6, F Pène7, L Papazian8, F Bruneel9, A Seguin10, A Kouatchet11, J Oziel12, S Rouleau13, N Bele14, K Razazi15, O Lesieur16, F Boissier17, B Megarbane18, N Bigé19, N Brulé20, A S Moreau21, A Lautrette22, O Peyrony23, P Perez24, J Mayaux25, E Azoulay5,3.
Abstract
BACKGROUND: Chlamydophila pneumoniae (CP) and Mycoplasma pneumoniae (MP) patients could require intensive care unit (ICU) admission for acute respiratory failure.Entities:
Keywords: Chlamydophila pneumoniae; ICU; Mycoplasma pneumoniae; Outcome; Pneumonia
Year: 2018 PMID: 30105627 PMCID: PMC6089852 DOI: 10.1186/s13613-018-0429-z
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Fig. 1Distribution of atypical pneumonia cases by season and year
Clinical characteristics of patients with atypical pneumonia at ICU admission and outcome according to the causative agent
| Total ( | |||
|---|---|---|---|
| Demographics | |||
| Age | 56 [44–67] | 54 [41–69] | 64 [52–75] |
| Female gender | 33 (32%) | 26 (34%) | 7 (25%) |
| Comorbidities | |||
| Chronic respiratory disease | 32 (31%) | 22 (29%) | 10 (36%) |
| Current smoker | 30 (29%) | 20 (38%) | 10 (36%) |
| Immunosuppression | 21 (20%) | 17 (22%) | 4 (14%) |
| HIV infection | 2 (2%) | 2 (3%) | 0 |
| Hematological malignancy | 10 (10%) | 9 (12%) | 1 (3.5%) |
| Cancer | 7 (7%) | 4 (5%) | 3 (11%) |
| Hypertension | 32 (31%) | 24 (32%) | 8 (28%) |
| Reason for ICU admission | |||
| Acute respiratory distress | 96 (92%) | 70 (92%) | 26 (93%) |
| Cardiovascular failure | 2 (2%) | 2 (3%) | 0 |
| Neurological disorders | 3 3%) | 2 (3%) | 1 (3.6%) |
| Other | 3 (3%) | 2 (3%) | 1 (3.6%) |
| Clinical respiratory findings | |||
| Respiratory rate | 32 [26–37] | 33 [27–38] | 30 [26–33] |
| Signs of respiratory failure | 48 (46%) | 33 (49%) | 15 (54%) |
| Rhonchi | 15 (14%) | 9 (15%) | 6 (21%) |
| Crackles | 54 (52%) | 36 (47%) | 18 (64%) |
| Signs of consolidation | 7 (7%) | 5 (9%) | 2 (7%) |
| Decreased vesicular breath sounds | 14 (13%) | 10 (17%) | 4 (14%) |
| Clinical presentation | |||
| Time since symptom onset (days) | 5 [3–8] | 6 [4–9] | 4 [2–7] |
| Fever | 77 (74%) | 58 (83%) | 19 (68%) |
| Shock | 10 (10%) | 6 (8%) | 4 (14%) |
| Neurological symptoms | 32 (31%) | 19 (25%) | 13 (46%) |
| Gastrointestinal symptoms | 1 (1%) | 1 (1%) | 0 |
| Extra-pulmonary signs | |||
| ≥ 1 extra-pulmonary symptom | 34 (33%) | 27 (36%) | 7 (25%) |
| Arthritis | 2 (2%) | 1 (1%) | 1 (3.5%) |
| Myocarditis | 4 (4%) | 4 (5%) | 0 |
| Treatments in the ICU | |||
| Mechanical ventilation | 75 (72%) | 50 (66%) | 25 (89%) |
| Duration of ventilation | 13 [8–19] | 12.5 [8–22.5] | 13.5 [8.5–19] |
| Vasopressors | 41 (39%) | 26 (34%) | 15 (54%) |
| Renal replacement therapy | 10 (9.5%) | 7 (9%) | 3 (11%) |
| Outcomes | |||
| Death in the ICU | 11 (10%) | 6 (8%) | 5 (18%) |
| Length of ICU stay (days) | |||
| Discharged alive | 15 [8–26] | 15 [8–27] | 19 [12–24] |
| ICU death | 39 [25–49] | 37 [26–47] | 39 [25–90] |
HIV human immunodeficiency virus, ICU intensive care unit
Univariate analysis comparing clinical characteristics and outcomes of patients with Mycoplasma pneumoniae versus Streptococcus pneumoniae pneumonia
| Total ( | ||||
|---|---|---|---|---|
| Demographics | ||||
| Age | 55 [43–69] | 54 [41–69] | 57 [44–73] | 0.058 |
| Female gender | 51 (34%) | 26 (34%) | 25 (33%) | 1 |
| Comorbidities | ||||
| Chronic respiratory disease | 36 (24%) | 22 (29%) | 14 (18%) | 0.18 |
| Current smoker | 49 (41%) | 20 (38%) | 29 (43%) | |
| Immunosuppression | 44 (29%) | 17 (22%) | 27 (36%) | 0.11 |
| HIV infection | 14 (9%) | 2 (3%) | 12 (16%) |
|
| Hematological malignancy | 18 (12%) | 9 (12%) | 9 (12%) | 1 |
| Cancer | 12 (8%) | 4 (5%) | 8 (11%) | 0.37 |
| Hypertension | 50 (33%) | 24 (32%) | 26 (34%) | 0.86 |
| Reason for ICU admission | ||||
| Acute respiratory distress | 140 (92%) | 70 (92%) | 70 (92%) | 0.59 |
| Shock | 6 (4%) | 2 (3%) | 4 (5%) | |
| Neurological symptoms | 4 (3%) | 2 (3%) | 2 (3%) | |
| Other | 2 (1%) | 2 (3%) | 0 | |
| Clinical respiratory findings | ||||
| Respiratory rate | 31 [26–38] | 33 [27–38] | 30 [26–36] | 0.43 |
| Signs of respiratory distress | 67 (47%) | 33 (49%) | 34 (45%) | 0.74 |
| Rhonchi | 21 (16%) | 9 (15%) | 12 (16%) | 1 |
| Crackles | 79 (59%) | 36 (61%) | 44 (59%) | 1 |
| Signs of consolidation | 27 (21%) | 5 (9%) | 22 (30%) |
|
| Decreased vesicular breath sounds | 38 (28%) | 10 (17%) | 28 (38%) |
|
| Clinical presentation | ||||
| Time since symptom onset (days) | 4 [2–7] | 6 [4–9] | 3 [2–7] |
|
| Fever | 112 (77%) | 58 (83%) | 54 (71%) | 0.12 |
| Shock | 30 (20%) | 6 (8%) | 24 (32%) |
|
| Neurological symptoms | 21 (14%) | 1 (1%) | 20 (26%) |
|
| Gastrointestinal symptoms | 16 (11%) | 1 (1%) | 15 (20%) |
|
| Extra-pulmonary signs | ||||
| ≥ 1 extra-pulmonary sign | 66 (43%) | 27 (36%) | 39 (51%) | 0.071 |
| Arthritis | 1 (1%) | 1 (1%) | 0 | 1 |
| Myocarditis | 4 (3%) | 4 (5%) | 0 | 0.12 |
| Treatments in the ICU | ||||
| Mechanical ventilation | 88 (58%) | 50 (66%) | 38 (50%) |
|
| Duration of ventilation (days) | ||||
| Discharged alive | 11 [7–19] | 13 [8–23] | 9 [6–16] | |
| ICU death | 11 [3–18] | 18 [17–34] | 5 [2–15] | |
| Vasopressors | 60 (39%) | 26 (34%) | 34 (45%) | 0.26 |
| Renal replacement therapy | 17 (11%) | 7 (9%) | 10 (13%) | 0.49 |
|
| 36 [24–47] | 32 [22–41] | 42 [30–55] |
|
| Outcomes | ||||
| ICU stay length (days) | ||||
| Discharged alive | 9 [5–19] | 15 [8–27] | 5 [3–10] | |
| ICU death | 13 [4–27] | 37 [26–47] | 5 [3–14] | |
| 28-day mortality | 23 (15%) | 6 (8%) | 17 (22%) |
|
HIV human immunodeficiency virus, ICU intensive care unit, SAPS II Simplified Acute Physiology Score version II
Univariate analysis comparing laboratory findings in patients with Mycoplasma pneumoniae versus Streptococcus pneumoniae pneumonia
| Total ( | ||||
|---|---|---|---|---|
| Laboratory features | ||||
| Lactate (mmol/l) | 2.2 [1.6–3.3] | 1 [0.7–2.7] | 2.3 [1.8–3.4] | 0.003 |
| P/F ratio | 163 [92–267] | 120 [88–236] | 178 [114–280] | 0.051 |
| Serum sodium (mmol/L) | 136 [133–139] | 137 [135–140] | 136 [132–139] |
|
| Creatinine (µmol/L) | 87 [65–139.5] | 77 [57.5–108] | 101 [69.5–168.8] |
|
| CPK (IU/l) | 122 [40–309] | 138 [89–608] | 108 [36–202] | 0.093 |
| ASAT (IU/l) | 38 [23–80] | 44 [24–81] | 38 [22–77] | 0.45 |
| Bilirubin (µmol/l) | 12.8 [8–21.7] | 8.4 [5.8–13] | 15 [9.2–24.5] |
|
| Leukocytes | 11,400 [7200–16,300] | 11,140 [8100–17,000] | 11,200 [5112–16,142] | 0.63 |
| Hemoglobin (g/dL) | 11.6 [10–12.9] | 11.3 [9.6–13.1] | 11.6 [10.2–12.8] | 0.89 |
| Platelets (Giga/L) | 217 [138–287] | 262.5 [179.5–311.25] | 204 [138–252] |
|
| Cytolysis | 21 (14%) | 8 (11%) | 13 (17%) | 0.35 |
| Hemolytic anemia/cold agglutinins | 9 (6%) | 9 (12%) | 0 |
|
| Rhabdomyolysis | 5 (3%) | 2 (3%) | 3 (4%) | 1 |
| Radiological features | ||||
| Number of quadrants involved |
| |||
| ≤ 2 | 103 (68%) | 37 (49%) | 66 (87%) | |
| > 2 | 25 (16%) | 16 (21%) | 9 (12%) | |
| Alveolar opacities | 111 (85%) | 42 (75%) | 19 (68%) |
|
| Interstitial opacities | 26 (20%) | 20 (36%) | 12 (43%) |
|
| Pleural effusion | 20 (15%) | 3 (5%) | 3 (11%) |
|
P/F ratio ratio of partial pressure of oxygen in arterial blood over fraction of inspired oxygen, CPK creatine phosphokinase, ASAT aspartate aminotransferase
Fig. 2Multiple correspondence analysis: the factors are mapped along two dimensions. Triangles indicate pulmonary signs and squares extra-pulmonary signs. HA hemolytic anemia, Cold agglu+ presence of cold agglutinins, QD quadrants